Kenneth Fletcher Olson
CIK 1793360 · View on SEC EDGAR ↗
First SEC filing: Dec. 30, 2021 · Latest: Dec. 30, 2021
On this page
Insider at
Insider transactions
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
No open-market trades on record; showing all filings.
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| Dec. 29, 2021 | HBIO | F | 3,347 | $7.27 | $24,333 | 155,595 Direct | -2.11% | Disposed | -89.6% (price as of 2026-08-21) |
| Dec. 29, 2021 | HBIO | F | 2,812 | $7.27 | $20,443 | 158,942 Direct | -1.74% | Disposed | -89.6% (price as of 2026-08-21) |
| Nov. 1, 2021 | HBIO | F | 1,539 | $7.37 | $11,342 | 161,754 Direct | -0.94% | Disposed | -89.7% (price as of 2026-08-21) |
| June 11, 2021 | HBIO | F | 6,480 | $7.64 | $49,507 | 163,293 Direct | -3.82% | Disposed | -90.1% (price as of 2026-08-21) |
| June 11, 2021 | HBIO | A | 18,378 | — | — | 169,773 Direct | +12.14% | Acquired | (price as of 2026-08-21) |
| March 1, 2021 | HBIO | A | 31,453 | — | — | 151,395 Direct | +26.22% | Acquired | (price as of 2026-08-21) |
| March 1, 2021 | HBIO | A | 32,805 | — | — | 119,942 Direct | +37.65% | Acquired | (price as of 2026-08-21) |
| Dec. 31, 2020 | HBIO | F | 3,299 | $4.29 | $14,153 | 87,137 Direct | -3.65% | Disposed | -82.3% (price as of 2026-08-21) |
| Nov. 1, 2020 | HBIO | F | 1,806 | $3.46 | $6,249 | 86,792 Direct | -2.04% | Disposed | -78.1% (price as of 2026-08-21) |
| Nov. 1, 2020 | HBIO | D | 1,863 | — | — | 88,598 Direct | -2.06% | Disposed | (price as of 2026-08-21) |
| June 11, 2020 | HBIO | A | 36,756 | — | — | 53,705 Direct | +216.86% | Acquired | (price as of 2026-08-21) |
| June 11, 2020 | HBIO | A | 36,756 | — | — | 90,461 Direct | +68.44% | Acquired | (price as of 2026-08-21) |
| June 11, 2020 | HBIO | A | 79,235 | — | — | 79,235 Direct | — | Acquired | (price as of 2026-08-21) |
| Nov. 1, 2019 | HBIO | A | 16,949 | — | — | 16,949 Direct | — | Acquired | (price as of 2026-08-21) |
| Nov. 1, 2019 | HBIO | A | 37,037 | — | — | 37,037 Direct | — | Acquired | (price as of 2026-08-21) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II)
Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| June 11, 2020 | HBIO | Stock option (right to buy) | Common Stock (79,235) | $2.63 | June 11, 2027 | 79,235 | Acquired |
| Nov. 1, 2019 | HBIO | Stock option (right to buy) | Common Stock, par value $0.01 per share (37,037) | $2.95 | Nov. 1, 2029 | 37,037 | Acquired |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2022 | $290,000 | — | — | — | — | — | — | $307,940 |
| 2021 | $290,000 | — | $290,000 | — | $98,600 | — | $25,711 | $704,311 |
| 2020 | $285,263 | $54,416 | $206,196 | $96,667 | — | — | $186,540 | $829,082 |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.